您所在的位置: 首页 --> 导师团队 --> 沈琳

导师基本信息

  • 姓名:沈琳
  • 性别:
  • 民族:汉族
  • 科室:消化肿瘤内科
  • 职称:主任医师 ,教授
  • 专业:肿瘤学 ,肿瘤内科学
  • E-MAIL: lin100@medmail.com.cn

学术论文 | 出版专著 | 奖励表彰 | 研究方向 | 招生计划

Koo DH, Ryu MH, Kim KM, Yang HK, Sawaki A, Hirota S, Zheng J, Zhang B, Tzen CY, Yeh CN, Nishida T, Shen L, Chen LT, Kang YK. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. Cancer Res Treat. , 48(4):1155-1166.

Xu RH, Shen L, Li J, Xu JM, Bi F, Ba Y, Bai L, Shu YQ, Liu TS, Li YH, Bai CM, Yuan XL, Zhang J, Chen G, Zhou AP, Yuan Y, Wang XJ, Qian XP, Deng YH. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Chin J Cancer. ,35:13-8.

Tejpar S*, Shen L*, Wang X, Schilsky RL.Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. ,12(9):553-60

Lin X#, Peng Z#, Wang X, Zou J, Chen D, Chen Z, Li Z, Dong B, Gao J*, Shen L*. Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer. Cell Death Dis. ,2019; 10(2):139-149.

Li J*, Xu R*, Qin S, Liu T, Pan H, Xu J, Bi F, Lim R, Zhang S, Ba Y, Bai Y, Fan N, Tsuji A, Yeh KH, Ma B, Wei V, Shi D, Magherini E, Shen L#. Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. Future Oncol. ,2018;14(20):2031-2044.

Zhang C*, Qu L*, Lian S, Meng L, Min L, Liu J, Song Q, Shen L#, Shou C#. PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1. Cancer Res. ,2018 Nov 29. pii: canres.0520.2018.

Chen Z#, Liu Z#, Zhang M, Huang W, Li Z, Wang S, Zhang C, Dong B, Gao J*, Shen L*. EPHA2 blockade reverses acquired resistance to afatinib induced by EPHA2-mediated MAPK pathway activation in gastric cancer cells and avatar mice. Int J Cancer. ,

Li Y*, Zhang X*, Liu D, Gong J, Wang D, Li S, Peng Z, Li Y, Wang X, Lin P, Li M, Shen L#. Evolutionary expression of HER2 conferred by chromosome aneuploidy on circulating gastric cancer cells contributes to developing targeted and chemotherapeutic resistance. Clin Cancer Res. , 2018; 24(21):5261-5271.

Zou J*, Li S, Chen Z, Lu Z, Gao J, Zou J, Lin X, Li Y, Zhang C#, Shen L#. A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo. Cell Death Dis. ,2018; 9(6):661.

Lu Z*, Zhang X*, Liu W*, Liu T*, Hu B, Li W, Fan Q, Xu J, Xu N, Bai Y, Pan Y, Xu Q, Bai W, Xia L, Gao Y, Wang W, Shu Y, Shen L#. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. ,2018;21(5):782-791.

Zou J*, Liu Y*, Wang J, Liu Z, Lu Z, Chen Z, Li Z, Dong B, Huang W, Li Y, Gao J#, Shen L#. Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization. J Transl Med. ,2018; 16(1):15-25.

Lin X*, Chen D*, Zhang C, Zhang X, Li Z, Dong B, Gao J#, Shen L#. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathway and DNA damage checkpoint. J Exp Clin Cancer Res. ,2018; 37(1):129.

Chen Z, Huang W, Tian T, Zang W, Wang J, Liu Z, Li Z, Lai Y, Jiang Z, Gao J*, Shen L*. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer. J Hematol Oncol. ,2018; 11(1):20-31.

Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, Niu Y, Bo S, Li Z, Lai Y, Lu S*, Gao J*, Shen L*. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. ,2018; 88:92-100.

Liu Z*, Chen Z*, Wang J, Zhang M, Li Z, Wang S, Dong B, Zhang C, Gao J#, Shen L#. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance. J Hematol Oncol. , 2018; 11(1):109.

Wang L, Li Y, Xu J, Zhang A, Wang X, Tang R, Zhang X, Yin H, Liu M, Wang DD, Lin PP, Shen L*, Dong J*. Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett. , 2018; 412:99-107.

Wang J, Liu Z, Wang Z, Wang S, Chen Z, Li Z, Zhang M, Zou J, Dong B, Gao J*, Shen L*. Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma. Cancer Lett. ,2018; 419:64-74.

Ge S, Xia X, Ding C, Zhen B*, Zhou Q, Feng J, Yuan J, Chen R, Li Y, Ge Z, Ji J, Zhang L, Wang J, Li Z, Lai Y, Hu Y, Li Y, Li Y, Gao J, Chen L, Xu J, Zhang C, Jung SY, Choi JM, Jain A, Liu M, Song L, Liu W, Guo G, Gong T, Huang Y, Qiu Y, Huang W, Shi T, Zhu W, Wang Y, He F*, Shen L*, Qin J*. A proteomic landscape of diffuse-type gastric cancer. Nat Commun. , 2018; 9(1): 1012-1027.

Yuan J, Zhang J, Zhu Y, Li N, Tian T, Li Y, Li Y, Li Z, Lai Y, Gao J, Shen L. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. Oncotarget. ,7(26): 36971-9.

Ge S, Zhang Q, He Q, Zou J, Liu X, Li N, Tian T, Zhu Y, Gao J, Shen L. Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts. Oncol Lett. ,12: 1763-8.

Yuan J, Li Y, Tian T, Li N, Zhu Y, Zou J, Gao J, Shen L. Risk prediction for early-onset gastric carcinoma: a case-control study of polygenic gastric caner in Han Chinese with hereditary background. Oncotarget. ,7(23): 33608-15.

Li N, Zhang QY, Zou JL, Li ZW, Tian TT, Dong B, Liu XJ, Ge S, Zhu Y, Gao J, Shen L. miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget. ,7(4): 4817-28.

Wei Q, Wang X, Gao J, Li J, Li J, Qi C, Li Y, Li Z, Shen L. Clinicopathologic and molecular features of colorectal adenocarcinoma with signet-ring cell component. PLoS One. ,11(6): e0156659.

Tian T, Gao J, Li N, Li Y, Lu M, Li Z, Lu Z, Li J, Shen L. Circulating chromogranin A as a marker for monitoring clinical response in advanced gastroenteropancreatic neuroendocrine tumors. PLoS One. ,11(5): e0154679.

Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, Zhou L, Jia L, Huang X, Kang Q, Lin D, Gao J, Shen L. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. ,55: 182-9.

Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. ,14(1): 305-15.

Wang Q, Zhang X, Shen E, Gao J, Cao F, Wang X, Li Y, Tian T, Wang J, Chen Z, Wang J, Shen L. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer. Cancer Lett. ,380(1): 20-30.

Li Y, Gong J, Zhang Q, Lu Z, Gao J, Li Y, Cao Y, Shen L. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. 2016; Br J Cancer. ,114(2): 138-45.

Gao J, Li J, Li Y, Li Z, Gong J, Wu J, Liu N, Dong B, Qi C, Li J, Shen L. Intratumoral KIT mutational heterogeneity and recurrent KIT/PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors. Oncotarget. ,7(21): 30241-9.

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, Liu W, Wang L, Shen L. Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. ,16:68-76.

Kou F, Lu Z, Li J, Zhang X, Lu M, Zhou J, Wang X, Gong J, Gao J, Li J, Li Y, Shen L. Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. Cancer Med. ,5(5): 778-86.

Lu M, Yang Z, Feng Q, Yu M, Zhang Y, Mao C, Shen L, Tang J. The characteristics and prognostic value of signet ring cell histology in gastric cancer: A retrospective cohort study of 2199 consecutive patients. Medicine (Baltimore). ,95(27): e4052.

Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, Dai G, Xu J, Liu Y, Fan N, Shu Y, Ba Y, Ma D, Qin S, Zheng L, Chen W, Shen L*. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric cancer ,19(1): 234-44

J Gao#, N Li#, Y Dong, S Li, L Xu, X Li, Y Li, Z Li, SS Ng, JJ Sung, L Shen* and J Yu*. miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. oncogene ,348

Peng Z, Li Z#, Gao J, Lu M, Gong JF, Tang ET, Oliner KS, Hei YJ, Zhou H, Shen L*.Tumor MET Expression and Gene Amplification in Chinese Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. ,14(11): 2634-41

Zhu Y, Tian T, Zou J, Wang Q, Li Z, Li Y, Liu X, Dong B, Li N, Gao J, Shen L. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. BMC Cancer. ,15(1): 894-903.

Peng Z, Zou J, Zhang X, Yang Y, Gao J, Li Y, Li Y, Shen L. HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis. Chin J Cancer Res. ,27(2):163-71.

Li J, Dang Y#, Gao J, Li Y, Zou J, Shen L*.PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs) Medical Oncology ,32:111-117

Zhu Y#, Tian T#, Li Z, Tang Z, Wang L, Wu J, Li Y, Dong B, Li Y, Li N, Zou J, Gao J*, Shen L*. Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer Scientific Reports ,5: 8542-9

Zhou J#, Peng Z#, Liu Y, Gong J, Zhang X, Lu M, Gao J, Li Y, Li Y, Shen L*. Predictive value of serum HER2 ECD in patients with HER2-positive advanced gastric cancer treated with trastuzumab plus chemotherapy J Gastroenterol. ,50(9): 955-61

Yingying Xu#, Zhi Peng#, Zhongwu Li, Ming Lu, Jing Gao, Yilin Li, Yanyan Li and Lin Shen* Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma BMC cancer ,15:6-12

Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastaticgastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer ,18:168–176

Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, Shen L. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients withadvanced gastric cancer. Chin J Cancer Res. ,28(6):579-588.

Li Y, Zhang X, Gong J, Zhang Q, Gao J, Cao Y, Wang DD, Lin PP, Shen L. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chinese Journal of Cancer Research ,2016;28(6):579-588.

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis BMC CANCER ,2017;17:437

Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study Chinese Journal of Cancer ,2017;36:81

Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z, Li Z, Lai Y, Gao J, Shen L. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cellcarcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. ,15(1):127-37.

Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study ONCOTARGET ,2017;8(15):25669-25678

Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer CANCER SCIENCE ,2017;108(9):1881-1887

Genomic alterations in advanced gastric cancer endoscopic biopsy samples using targeted next-generation sequencing AMERICAN JOURNAL OF CANCER RESEARCH ,2017;7(7):1540-1553

Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study ONCOTARGET ,2017;8(26);42076-42086

Kuang P, Chen Z, Wang J, Liu Z, Wang J, Gao J, Shen L. Characterization of Aurora A and its impact on the effect of cisplatin-based chemotherapy in patients with non-small cell lung cancer. Transl Oncol. ,10(3):367-377.

Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor. Chinese journal of cancer research ,2017;29(4):281-293

2017.1,消化道恶性肿瘤合理用药指南

2016.11,以分子分型为基础的晚期胃癌精准治疗体系的初步建立

2017.12,胃癌综合防治体系关键技术的创建及其应用

2017.1,胃癌综合防治体系关键技术的创建及其应用

2017.2,胃癌综合防治体系关键技术的创建及其应用

2017.11,适合中国人群特征的胃肠间质瘤个体化药物治疗体系的建立

研究生招生计划
招生年度 招生专业 学位级别 学位类型 研究方向 选拔方式
2020 肿瘤内科学 博士 专业学位 临床医疗技能训练与研究 申请考核制
2020 肿瘤内科学 硕士 专业学位 临床医疗技能训练与研究 全国统考

学习、工作经历

  • 1996.10.1~2080.12.31,北京肿瘤医院,工作
  • 1995.8.1~1996.9.1,徐州医学院附属医院内科,工作
  • 1984.8.1~1992.8.1,徐州医学院附属医院内科,工作
  • 2000.6.1~2001.6.1,美国NIH/NIDDK,访问学者
  • 1992.9.1~1995.7.1,北京医科大学,研究生学习
  • 1979.9.1~1984.7.1,徐州医学院,本科学习